Long-term Renal Outcomes of Patients With Type 1 Diabetes Mellitus and Microalbuminuria An Analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Cohort

被引:257
作者
de Boer, Ian H. [1 ,2 ]
Rue, Tessa C. [3 ]
Cleary, Patricia A. [5 ]
Lachin, John M. [5 ]
Molitch, Mark E. [6 ]
Steffes, Michael W. [7 ]
Sun, Wanjie [5 ]
Zinman, Bernard [8 ]
Brunzell, John D. [4 ]
机构
[1] Univ Washington, Kidney Res Inst, Seattle, WA 98104 USA
[2] Univ Washington, Dept Med, Div Nephrol, Seattle, WA 98104 USA
[3] Univ Washington, Dept Biostat, Seattle, WA 98104 USA
[4] Univ Washington, Dept Med, Div Metab Endocrinol & Metab, Seattle, WA 98104 USA
[5] George Washington Univ, Ctr Biostat, Rockville, MD USA
[6] Northwestern Univ, Chicago, IL 60611 USA
[7] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[8] Univ Toronto, Dept Med, Toronto, ON, Canada
关键词
ALBUMIN EXCRETION RATE; NEPHROPATHY; PROGRESSION; EPIDEMIOLOGY; PREDICTORS; RISK; MACROALBUMINURIA; INTERVENTIONS; PROTEINURIA; IRBESARTAN;
D O I
10.1001/archinternmed.2011.16
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Microalbuminuria is a common diagnosis in the clinical care of patients with type 1 diabetes mellitus. Long-term outcomes after the development of microalbuminuria are variable. Methods: We quantified the incidence of and risk factors for long-term renal outcomes after the development of microalbuminuria in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. The DCCT randomly assigned 1441 persons with type 1 diabetes to intensive or conventional diabetes therapy, and participants were subsequently followed up during the observational EDIC study. During the DCCT/EDIC study, 325 participants developed incident persistent microalbuminuria (albumin excretion rate, >= 30 mg/24 h at 2 consecutive study visits). We assessed their subsequent renal outcomes, including progression to macroalbuminuria (albumin excretion rate, >= 300 mg/24 h at 2 consecutive visits), impaired glomerular filtration rate (estimated glomerular filtration rate, < 60 mL/min/1.73 m(2) at 2 consecutive study visits), end-stage renal disease, and regression to normoalbuminuria (albumin excretion rate, < 30 mg/24 h at 2 consecutive visits). Results: The median follow-up period after persistent microalbuminuria diagnosis was 13 years( maximum, 23 years). Ten-year cumulative incidences of progression to macroalbuminuria, impaired glomerular filtration rate, end-stage renal disease, and regression to normoalbuminuria were 28%, 15%, 4%, and 40%, respectively. Albuminuria outcomes were more favorable with intensive diabetes therapy, lower glycated hemoglobin level, absence of retinopathy, female sex, lower blood pressure, and lower concentrations of low-density lipoprotein cholesterol and trigly cerides. Lower glycated hemoglobin level, absence of retinopathy, and lower blood pressure were also associated with decreased risk of impaired glomerular filtration rate. Conclusions: After the development of persistent microalbuminuria, progression and regression of kidney disease each commonly occur. Intensive glycemic control, lower blood pressure, and a more favorable lipid profile are associated with improved outcomes.
引用
收藏
页码:412 / 420
页数:9
相关论文
共 38 条
  • [1] Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64)
    Adler, AI
    Stevens, RJ
    Manley, SE
    Bilous, RW
    Cull, CA
    Holman, RR
    [J]. KIDNEY INTERNATIONAL, 2003, 63 (01) : 225 - 232
  • [2] Multiple superoxide dismutase 1/splicing factor serine alanine 15 variants are associated with the development and progression of diabetic nephropathy
    Al-Kateb, Hussam
    Boright, Andrew P.
    Mirea, Lucia
    Xie, Xinlei
    Sutradhar, Rinku
    Mowjoodi, Afireza
    Bharaj, Bhupinder
    Liu, Michelle
    Bucksa, Jean M.
    Arends, Valerie L.
    Steffes, Michael W.
    Cleary, Patricia A.
    Sun, Wanjie
    Lachin, John M.
    Thorner, Paul S.
    Ho, Michael
    McKnight, Amy Jayne
    Maxwell, A. Peter
    Savage, David A.
    Kidd, Kenneth K.
    Kidd, Judith R.
    Speed, William C.
    Trevor, J. Orchard
    Miller, Rachel G.
    Sun, Lei
    Bull, Shelley B.
    Paterson, Andrew D.
    [J]. DIABETES, 2008, 57 (01) : 218 - 228
  • [3] Standards of Medical Care in Diabetes-2009
    不详
    [J]. DIABETES CARE, 2009, 32 : S13 - S61
  • [4] ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496
  • [5] In defense of pharmacoepidemiology - Embracing the yin and yan of drug research
    Avorn, Jerry
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (22) : 2219 - 2221
  • [6] Glycemic control and prognosis in type I diabetic patients with microalbuminuria
    Bojestig, M
    Arnqvist, HJ
    Karlberg, BE
    Ludvigsson, J
    [J]. DIABETES CARE, 1996, 19 (04) : 313 - 317
  • [7] PROTEINURIA - VALUE AS PREDICTOR OF CARDIOVASCULAR MORTALITY IN INSULIN-DEPENDENT DIABETES-MELLITUS
    BORCHJOHNSEN, K
    KREINER, S
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 1987, 294 (6588): : 1651 - 1654
  • [8] Genetic variation at the ACE gene is associated with persistent microalbuminuria and severe nephropathy in type 1 diabetes
    Boright, AP
    Paterson, AD
    Mirea, L
    Bull, SB
    Mowjoodi, A
    Scherer, SW
    Zinman, B
    [J]. DIABETES, 2005, 54 (04) : 1238 - 1244
  • [9] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [10] Microalbuminuria in type 1 diabetes: Rates, risk factors and glycemic threshold
    Chaturvedi, N
    Bandinelli, S
    Mangili, R
    Penno, G
    Rottiers, RE
    Fuller, JH
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (01) : 219 - 227